Nintedanib Onkogen (Nintedanib)

Nintedanib inhibits the kinase activity of several receptor tyrosine kinases, notably VEGFR, FGFR and PDGFR. By blocking these receptors it reduces endothelial cell proliferation, fibroblast activation and extracellular matrix formation, which together limit abnormal blood‑vessel growth and tissue scarring that characterize the approved disease states.

The specific dose and dosing schedule of Nintedanib Onkogen are determined by the prescribing clinician based on the patient’s condition, weight, renal and hepatic function, and other individual factors. Healthcare professionals should follow the latest prescribing information and adjust the regimen as clinically indicated.

Safety data for Nintedanib during pregnancy and lactation are limited. Because potential risks to the fetus or infant cannot be excluded, the drug is generally avoided in pregnant or nursing women unless the potential therapeutic benefit justifies the potential risk. Consultation with a specialist is recommended.

To request Nintedanib Onkogen, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent with a different mechanism of action. While both aim to slow disease progression, Nintedanib targets multiple tyrosine kinases and may have a broader anti‑angiogenic effect, whereas pirfenidone works mainly through anti‑inflammatory pathways. Choice depends on efficacy, tolerability, drug‑interaction profile and individual patient factors.

Nintedanib should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Keep the product out of reach of children and avoid exposure to excessive heat or humidity, which could compromise tablet integrity.

Nintedanib is taken orally, usually as a tablet swallowed whole with water. It is typically administered with food to reduce gastrointestinal discomfort, but patients should follow the specific instructions provided by their healthcare professional regarding timing and any dietary considerations.

Serious risks include liver injury (hepatotoxicity), arterial thromboembolic events such as stroke or myocardial infarction, severe bleeding, and gastrointestinal perforation. Patients should be monitored regularly for signs of liver dysfunction, cardiovascular symptoms, unexplained bleeding, or severe abdominal pain, and any concerning findings should prompt immediate medical evaluation.

Nintedanib is contraindicated in patients with known hypersensitivity to the active ingredient or any excipients, in those with active severe bleeding, recent major surgery, or uncontrolled cardiovascular disease. Caution is also advised for individuals with significant hepatic impairment, severe renal dysfunction, or those taking strong CYP3A4 inhibitors without appropriate dose adjustments.